Cargando…
Two Lung Masses with Different Responses to Pemetrexed
We described here a patient who had two lung masses. Although the two masses had the same histology and a similar good response to initial chemotherapy with gemcitabine and carboplatin, the response to pemetrexed as a second-line treatment was different after re-growth of the tumors. These two lung...
Autores principales: | Park, Kwang Young, Jung, Jae Wook, Nam, Seung Bum, Lee, Ho Jin, Kim, Hyo Seok, Choi, Yoon Hee, Lee, Jae Cheol |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880697/ https://www.ncbi.nlm.nih.gov/pubmed/20526397 http://dx.doi.org/10.3904/kjim.2010.25.2.213 |
Ejemplares similares
-
Predictive factors for long‐term responders of pemetrexed maintenance treatment in non‐small cell lung cancer
por: Yoon, Joon‐Young, et al.
Publicado: (2019) -
Exonuclease 1 genetic variant is associated with clinical outcomes of pemetrexed chemotherapy in lung adenocarcinoma
por: Hong, Mi Jeong, et al.
Publicado: (2022) -
Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed
por: Park, Sojung, et al.
Publicado: (2016) -
Genetic Variants in Histone Modification Regions Predict Clinical Outcomes of Pemetrexed Chemotherapy in Lung Adenocarcinoma
por: Lee, Yong Hoon, et al.
Publicado: (2023) -
Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung
por: Jung, Minkyu, et al.
Publicado: (2013)